Retatrutide vs Cagrilintide
Head-to-head comparison of Retatrutide and Cagrilintide for research applications. Both peptides are studied for Weight Management and Metabolic Health, but they differ significantly in mechanism, evidence level, and dosing protocols.
Side-by-Side Comparison
| Attribute | Retatrutide | Cagrilintide |
|---|---|---|
| Category | Metabolic / Triple Agonist | Metabolic / Amylin Analog |
| Mechanism | Retatrutide simultaneously activates three receptors: GLP-1 (reduces appetite, slows gastric emptying, improves insulin secretion), GIP (enhances insulin sensitivity, glucose control), and glucagon (increases energy expenditure, fat oxidation, thermogenesis). | Cagrilintide activates amylin receptors (calcitonin receptor + RAMP complexes) in the area postrema and other hindbrain regions, promoting meal-related satiety through distinct pathways from GLP-1 agonism. |
| Evidence Rating | B — Phase III / NDA Filed | B — Phase III / NDA Filed |
| Clinical Status | Phase 3 clinical trials (Eli Lilly TRIUMPH program) | Phase 3 (REDEFINE program). NDA filed with FDA in 2026 for CagriSema. |
| Safety Profile | GI side effects (dose-related, 13-63% across dose groups): nausea, vomiting, diarrhea, constipation; mostly mild to moderate; GI events partially mitigated with lower starting dose (2 mg vs 4 mg initial dose) | GI adverse events: 79.6% in CagriSema group vs 39.9% placebo (nausea, vomiting, diarrhea, constipation); GI events mainly transient and mild-to-moderate |
| Route | Subcutaneous (clinical trial formulation only) | Subcutaneous |
| Dose Range | Phase 2 tested 1, 4, 8, 12 mg weekly SC; optimal dose being determined in Phase 3 | Monotherapy: 1.2-4.5 mg weekly; CagriSema: fixed dose 2.4 mg cagrilintide + 2.4 mg semaglutide |
| Frequency | Once weekly | Once weekly |
| Molecular Weight | N/A | N/A |
| Half-Life | ~6 days (allows once-weekly dosing) | ~7 days (allows once-weekly dosing) |
Overview
Retatrutide and Cagrilintide are both research peptides studied across multiple applications. This comparison examines their mechanisms, evidence base, dosing protocols, and safety profiles to help researchers understand the key differences and overlaps.
Retatrutide — Mechanism & Evidence
Retatrutide is a first-in-class investigational triple hormone receptor agonist (GIP, GLP-1, and glucagon) developed by Eli Lilly. Multiple Phase 3 TRIUMPH trials are ongoing, with TRIUMPH-4 (Dec 2025) reporting average loss up to 71.2 lbs with osteoarthritis pain relief. Expected FDA approval is 2027-2028.
Key claims: Unprecedented weight loss in Phase 2; Phase 3 confirms efficacy with osteoarthritis benefit; Improves glycemic control in type 2 diabetes.
Cagrilintide — Mechanism & Evidence
Cagrilintide is a long-acting synthetic analog of human amylin, a peptide hormone co-secreted with insulin by pancreatic beta cells. It is being developed by Novo Nordisk both as a standalone agent and in fixed-dose combination with semaglutide (CagriSema). The CagriSema combination targets complementary appetite pathways — amylin acts on hindbrain satiety circuits while GLP-1 acts on hypothalamic and gut pathways. Novo Nordisk filed for FDA approval in 2026.
Key claims: CagriSema achieves ~20% weight loss; Superior to semaglutide alone; Standalone weight loss efficacy.
Shared Research Applications
Both peptides are studied for: Weight Management, Metabolic Health.
Retatrutide is also researched for: no additional unique applications.
Cagrilintide is also researched for: no additional unique applications.
Safety Considerations
Retatrutide: GI side effects (dose-related, 13-63% across dose groups): nausea, vomiting, diarrhea, constipation; mostly mild to moderate GI events partially mitigated with lower starting dose (2 mg vs 4 mg initial dose) Dose-dependent heart rate increases peaking at 24 weeks, declining thereafter
Cagrilintide: GI adverse events: 79.6% in CagriSema group vs 39.9% placebo (nausea, vomiting, diarrhea, constipation) GI events mainly transient and mild-to-moderate Similar safety profile to GLP-1 class: pancreatitis risk, gallbladder events, thyroid C-cell tumors in rodents
Shop Research Peptides
Retatrutide 20mg
20mg
Retatrutide 10mg
10mg
BPC-157 5mg
5mg
GHK-Cu 50mg
50mg
Tesamorelin 10mg
10mg
BPC-157 10mg
10mg
Tirzepatide 10mg
10mg
KPV 10mg
10mg
Quality Documentation
Review batch documentation before making research purchasing decisions. Volta pairs product education with COA literacy so researchers can evaluate purity, identity, lot details, and testing context.
Product cards on this page link to current catalog entries and available quality documentation.
Related Research News
Retatrutide Buy Online: Research Evidence and Limits
Retatrutide is a tri-agonist peptide under investigation, but no peer-reviewed study confirms over-the-counter availability. This article clarifies what evidence supports and what remains unproven.
Retatrutide in Canada: Evidence, Safety, and Access
This article clarifies retatrutide's tri-agonist mechanism, reviews the clinical evidence and its gaps, and outlines legal and safety considerations for Canadian research purchases.
Retatrutide vs Mounjaro: Evidence, Limits, and Tradeoffs
This reference evaluates how far current evidence supports using retatrutide over tirzepatide, highlighting that no head-to-head trial exists and that comparative outcomes remain unmeasured.
Peptide Tools
Follow Research Updates
Get new research pages, product updates, tool releases, and quality resources from Volta.
Subscribe